^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma

Published date:
01/11/2021
Excerpt:
CD206 expression on HLA-DRlow/- monocytes was associated with response to chemotherapy and overall survival….During treatment with RRx-001, reduced expression of the protumorigenic M2 marker CD206 on peripheral monocytes positively correlated with increased response and survival.
DOI:
10.1080/13543784.2021.1863947